


[Home](#) > [About Us](#) > [Cancer.Net Editorial Board](#) > [Associate Editors](#) > Robert G. Maki, MD, PhD, FACP

PDF generated on July 23, 2016 from

<http://www.cancer.net/about-us/cancernet-editorial-board/associate-editors/robert-g-maki-md-phd-facp>

Robert G. Maki, MD, PhD, FACP

maki_robert.jpg



Cancer.Net Associate Editor: Sarcoma

Mount Sinai School of Medicine, New York, NY

Dr. Robert Maki is Professor of Medicine, Pediatrics, and Orthopedics, and the Steven Ravitch Chair in Pediatric Hematology-Oncology at Mount Sinai School of Medicine in New York, NY. He has published over 120 peer-reviewed articles on sarcoma treatment and basic science research, having worked on studies related to sarcoma since 1985. He treats adults and adolescents with sarcomas, which are connective tissue cancers of bone, cartilage, muscle, fat and other soft tissue such as GIST, leiomyosarcoma, angiosarcoma, osteosarcoma and desmoid tumors.

Dr. Maki earned his medical and doctorate degree at Cornell University Medical College in New York City. He completed his residency at Brigham and Women's Hospital in Boston before completing his medical oncology fellowship at Dana-Farber, also in Boston. He is a fellow of the American College of Physicians.

One of the recognized U.S. and world thought leaders regarding sarcoma medical oncology, Dr. Maki has worked since 2011 at Mount Sinai Medical Center in New York to build lead their efforts in adult and pediatric sarcoma treatment and translational research. Dr. Maki has broad interests in the biology of sarcomas of soft tissue and bone, as well as clinical trials and new drug development for this diverse group of diseases, and he has participated extensively in numerous national and international studies in sarcoma.

Dr. Maki leads the Pediatric Hematology-Oncology program at Mount Sinai, where he continues his personal interest in the care of adolescents with sarcomas, while also expanding the role of the Pediatric Hematology-Oncology program in the treatment and research of pediatric cancers.

Disclosure: In the past two years, Dr. Maki has served as a consultant/advisor to Bayer, Lilly, GlaxoSmithKline, Eisai, Foundation Medicine; as of 2014 he receives research funding from SARC (Sarcoma Alliance for Research through Collaboration), Eisai and Lilly.
